Clinical Trial Detail

NCT ID NCT02278783
Title Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements no
Sponsors University of Utah
Indications

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.